百時美施貴寶 BMY 深 滬
已收盤 05-08 16:00:00 美东时间
56.16
-0.090
-0.16%
華盛通- 最 高56.535
- 今 開56.33
- 成交量 1003.30万股
- 最 低 55.775
- 昨 收 56.25
- 總市值 1146.83亿
- 52周最高 62.2564
- 市盈率 靜 16.23
- 換手率 0.49%
- 52周最低 41.08
- 委 比 -4.31%
- 總股本 20.42亿
- 歷史最高 73.015
- 量 比 0.84
- 振 幅 1.35%
- 歷史最低 1.85
- 每 手 1
- 風險率 6.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多全球药企研发投入TOP 15榜单揭晓！
默沙东 默沙东持续通过研发与收购扩展研发管线。今年3月，该公司斥资约67亿美元收购了Terns Pharmaceuticals，获得治疗慢性髓系白血病...
05-09 07:31
Bristol Myers Squibb Says European Commission Grants Approval To Sotyktu, Alone Or In Combination With Methotrexate, For Treatment Of Active Psoriatic Arthritis In Adults
In the pivotal Phase 3 POETYK PsA clinical trials, Sotyktu demonstrated superiority compared with placebo at Week 16 across multiple endpoints, including skin and joint symptoms, with improvements in quality of life as
05-08 19:00
BMS wins EU approval for Sotyktu to treat active psoriatic arthritis in adults
BMS wins EU approval for Sotyktu to treat active psoriatic arthritis in adults European Commission granted marketing authorization for Sotyktu (deucravacitinib) to treat active psoriatic arthritis in adults with inadequate response or intolerance to prior DMARD therapy. Label covers use as monothera
05-08 18:59
Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call
On Wednesday, Madrigal Pharmaceuticals (NASDAQ:MDGL) discussed first-quarter fi...
05-06 21:23
Tempus AI's Big Pharma AI Partnerships Are Getting Bigger And Stickier
Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook amid strong AI & diagnostic demand.
05-06 18:12
UPDATE 3-Pfizer posts strong first-quarter, sees boost from recent legal wins
UPDATE 3-Pfizer posts strong first-quarter, sees boost from recent legal wins New launches and acquired drugs offset COVID product declines Vyndamax patent extension and favorable EU court ruling expected to boost post-2028 growth First-quarter revenue and profit beat estimates on strong Eliquis sal
05-05 18:59
FACTBOX-Global pharma companies that have publicly announced Trump drug pricing agreements
FACTBOX-Global pharma companies that have publicly announced Trump drug pricing agreements Changes dateline, updates paragraph 1, adds Regeneron's deal details May 4 (Reuters) - U.S. President Donald Trump secured agreements with 17 major pharmaceutical companies to bring U.S. prescription drug pric
05-04 22:45
Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard
Out of 22 S&P 500 healthcare companies that reported results this week, 19 beat earnings expectations and 15 posted year-over-year EPS growth. All 22 companies recorded year-over-year revenue increase...
05-03 01:40
专利悬崖倒逼制药业加速并购，2026年或成“超级并购大年”
随着多款重磅药物专利即将在未来几年陆续到期，大型制药企业正以前所未有的紧迫感加速并购交易，2026年有望成为生物医药领域的“超级并购大年”。 数据显示...
05-01 22:55
百时美施贵宝(BMY)股票5月1日盘中下跌3.18%：投资者必看的核心信息
• 百时美施贵宝第一季度营收和每股收益均超出预期。 • Non-GAAP每股收益同比下降12%，毛利率有所收窄。 • 传统业务组合表现下滑，影响了公司的整体业绩。
05-01 17:17
公司簡介
公司名稱
|
百时美施贵宝
|
行業分類
|
制药
|
業務描述
|
百时美施贵宝是一家以“研发并提供创新药物，帮助患者战胜严重疾病”为使命的全球性生物制药公司。公司拥有约25000名员工。2016年，百时美施贵宝全球研发投入达近50亿美元，占全年产品净销售额的28%。
|
全球药企研发投入TOP 15榜单揭晓！
默沙东 默沙东持续通过研发与收购扩展研发管线。今年3月，该公司斥资约67亿美元收购了Terns Pharmaceuticals，获得治疗慢性髓系白血病...
05-09 07:31
Bristol Myers Squibb Says European Commission Grants Approval To Sotyktu, Alone Or In Combination With Methotrexate, For Treatment Of Active Psoriatic Arthritis In Adults
In the pivotal Phase 3 POETYK PsA clinical trials, Sotyktu demonstrated superiority compared with placebo at Week 16 across multiple endpoints, including skin and joint symptoms, with improvements in quality of life as
05-08 19:00
BMS wins EU approval for Sotyktu to treat active psoriatic arthritis in adults
BMS wins EU approval for Sotyktu to treat active psoriatic arthritis in adults European Commission granted marketing authorization for Sotyktu (deucravacitinib) to treat active psoriatic arthritis in adults with inadequate response or intolerance to prior DMARD therapy. Label covers use as monothera
05-08 18:59
Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call
On Wednesday, Madrigal Pharmaceuticals (NASDAQ:MDGL) discussed first-quarter fi...
05-06 21:23
Tempus AI's Big Pharma AI Partnerships Are Getting Bigger And Stickier
Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook amid strong AI & diagnostic demand.
05-06 18:12
UPDATE 3-Pfizer posts strong first-quarter, sees boost from recent legal wins
UPDATE 3-Pfizer posts strong first-quarter, sees boost from recent legal wins New launches and acquired drugs offset COVID product declines Vyndamax patent extension and favorable EU court ruling expected to boost post-2028 growth First-quarter revenue and profit beat estimates on strong Eliquis sal
05-05 18:59
FACTBOX-Global pharma companies that have publicly announced Trump drug pricing agreements
FACTBOX-Global pharma companies that have publicly announced Trump drug pricing agreements Changes dateline, updates paragraph 1, adds Regeneron's deal details May 4 (Reuters) - U.S. President Donald Trump secured agreements with 17 major pharmaceutical companies to bring U.S. prescription drug pric
05-04 22:45
Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard
Out of 22 S&P 500 healthcare companies that reported results this week, 19 beat earnings expectations and 15 posted year-over-year EPS growth. All 22 companies recorded year-over-year revenue increase...
05-03 01:40
专利悬崖倒逼制药业加速并购，2026年或成“超级并购大年”
随着多款重磅药物专利即将在未来几年陆续到期，大型制药企业正以前所未有的紧迫感加速并购交易，2026年有望成为生物医药领域的“超级并购大年”。 数据显示...
05-01 22:55
百时美施贵宝(BMY)股票5月1日盘中下跌3.18%：投资者必看的核心信息
• 百时美施贵宝第一季度营收和每股收益均超出预期。 • Non-GAAP每股收益同比下降12%，毛利率有所收窄。 • 传统业务组合表现下滑，影响了公司的整体业绩。
05-01 17:17
派息除權日
|
每股總股息
| 派息日期 |
2026-04-02
|
0.63
|
2026-05-01
|
2026-01-02
|
0.63
|
2026-02-02
|
2025-10-03
|
0.62
|
2025-11-03
|
2025-07-03
|
0.62
|
2025-08-01
|
2025-04-04
|
0.62
|
2025-05-01
|
2025-01-03
|
0.62
|
2025-02-03
|
2024-10-04
|
0.60
|
2024-11-01
|
2024-07-05
|
0.60
|
2024-08-01
|
2024-04-04
|
0.60
|
2024-05-01
|
2024-01-04
|
0.60
|
2024-02-01
|
2023-10-05
|
0.57
|
2023-11-01
|
2023-07-06
|
0.57
|
2023-08-01
|
2023-04-06
|
0.57
|
2023-05-01
|
2023-01-05
|
0.57
|
2023-02-01
|
2022-10-06
|
0.54
|
2022-11-01
|
2022-06-30
|
0.54
|
2022-08-01
|
2022-03-31
|
0.54
|
2022-05-02
|
2022-01-06
|
0.54
|
2022-02-01
|
2021-09-30
|
0.49
|
2021-11-01
|
2021-07-01
|
0.49
|
2021-08-02
|
2021-03-31
|
0.49
|
2021-05-03
|
2020-12-31
|
0.49
|
2021-02-01
|
2020-10-01
|
0.45
|
2020-11-02
|
2020-07-02
|
0.45
|
2020-08-03
|
2020-04-02
|
0.45
|
2020-05-01
|
2020-01-02
|
0.45
|
2020-02-03
|
2019-10-03
|
0.41
|
2019-11-01
|
2019-07-03
|
0.41
|
2019-08-01
|
2019-04-04
|
0.41
|
2019-05-01
|
2019-01-03
|
0.41
|
2019-02-01
|
2018-10-04
|
0.40
|
2018-11-01
|
2018-07-05
|
0.40
|
2018-08-01
|
2018-04-05
|
0.40
|
2018-05-01
|
2018-01-04
|
0.40
|
2018-02-01
|
2017-10-05
|
0.39
|
2017-11-01
|
2017-07-05
|
0.39
|
2017-08-01
|
2017-04-05
|
0.39
|
2017-05-01
|
2017-01-04
|
0.39
|
2017-02-01
|
2016-10-05
|
0.38
|
2016-11-01
|
2016-06-29
|
0.38
|
2016-08-01
|
2016-03-30
|
0.38
|
2016-05-02
|
2015-12-30
|
0.38
|
2016-02-01
|
2015-09-30
|
0.37
|
2015-11-02
|
2015-07-01
|
0.37
|
2015-08-03
|
2015-04-01
|
0.37
|
2015-05-01
|
2014-12-30
|
0.37
|
2015-02-02
|
2014-10-01
|
0.36
|
2014-11-03
|
2014-07-01
|
0.36
|
2014-08-01
|
2014-04-02
|
0.36
|
2014-05-01
|
2013-12-31
|
0.36
|
2014-02-03
|
2013-10-02
|
0.35
|
2013-11-01
|
2013-07-02
|
0.35
|
2013-08-01
|
2013-04-03
|
0.35
|
2013-05-01
|
2013-01-02
|
0.35
|
2013-02-01
|
2012-10-03
|
0.34
|
2012-11-01
|
2012-07-03
|
0.34
|
2012-08-01
|
2012-04-03
|
0.34
|
2012-05-01
|
2012-01-04
|
0.34
|
2012-02-01
|
2011-10-06
|
0.33
|
2011-11-01
|
2011-06-29
|
0.33
|
2011-08-01
|
2011-03-30
|
0.33
|
2011-05-02
|
2011-01-05
|
0.33
|
2011-02-01
|
2010-09-29
|
0.32
|
2010-11-01
|
2010-06-30
|
0.32
|
2010-08-02
|
2010-03-30
|
0.32
|
2010-05-03
|
2009-12-30
|
0.32
|
2010-02-01
|
2009-09-30
|
0.31
|
2009-11-02
|
2009-07-01
|
0.31
|
2009-08-03
|
2009-04-01
|
0.31
|
2009-05-01
|
2008-12-30
|
0.31
|
2009-02-02
|
2008-10-01
|
0.31
|
2008-11-03
|
2008-07-02
|
0.31
|
2008-08-01
|
2008-04-02
|
0.31
|
2008-05-01
|
2008-01-02
|
0.31
|
2008-02-01
|
2007-10-03
|
0.28
|
2007-11-01
|
2007-07-03
|
0.28
|
2007-08-01
|
2007-04-03
|
0.28
|
2007-05-01
|
2007-01-03
|
0.28
|
2007-02-01
|
2006-10-04
|
0.28
|
2006-11-01
|
2006-07-05
|
0.28
|
2006-08-01
|
2006-04-05
|
0.28
|
2006-05-01
|
2006-01-04
|
0.28
|
2006-02-01
|
2005-10-05
|
0.28
|
2005-11-01
|
2005-06-29
|
0.28
|
2005-08-01
|
2005-03-30
|
0.28
|
2005-05-02
|
2005-01-05
|
0.28
|
2005-02-01
|
2004-09-29
|
0.28
|
2004-11-01
|
2004-06-30
|
0.28
|
2004-08-02
|
2004-03-31
|
0.28
|
2004-05-03
|
2003-12-30
|
0.28
|
2004-02-02
|
2003-10-01
|
0.28
|
2003-11-03
|
2003-07-01
|
0.28
|
2003-08-01
|
2003-04-02
|
0.28
|
2003-05-01
|
2002-12-31
|
0.28
|
2003-02-01
|
2002-10-02
|
0.28
|
2002-11-01
|
2002-07-02
|
0.28
|
2002-08-01
|
2002-04-03
|
0.28
|
2002-05-01
|
2002-01-02
|
0.28
|
2002-02-01
|
2001-10-03
|
0.28
|
2001-11-01
|
2001-07-03
|
0.28
|
2001-08-01
|
2001-04-04
|
0.28
|
2001-05-01
|
2001-01-03
|
0.28
|
2001-02-01
|
2000-10-04
|
0.25
|
2000-11-01
|
2000-07-05
|
0.25
|
2000-08-01
|
2000-04-05
|
0.25
|
2000-05-01
|
2000-01-05
|
0.25
|
2000-02-01
|
1999-09-29
|
0.22
|
1999-11-01
|
1999-06-30
|
0.22
|
1999-08-01
|
1999-03-30
|
0.22
|
1999-05-01
|
1999-01-06
|
0.43
|
1999-02-01
|
1998-09-30
|
0.39
|
1998-11-01
|
1998-06-30
|
0.39
|
1998-08-01
|
1998-04-01
|
0.39
|
1998-05-01
|
1997-12-30
|
0.39
|
1998-02-01
|
1997-10-01
|
0.38
|
1997-11-01
|
1997-07-01
|
0.38
|
1997-08-01
|
1997-04-02
|
0.38
|
1997-05-01
|
1996-12-31
|
0.76
|
1997-02-01
|
1996-10-02
|
0.75
|
1996-11-01
|
1996-07-02
|
0.75
|
1996-08-01
|
1996-04-02
|
0.75
|
1996-05-01
|
1996-01-03
|
0.75
|
1996-02-01
|
1995-10-04
|
0.74
|
1995-11-01
|
1995-07-05
|
0.74
|
1995-08-01
|
1995-04-03
|
0.74
|
1995-05-01
|
1994-12-30
|
0.74
|
1995-02-01
|
1994-10-03
|
0.73
|
1994-11-01
|
1994-06-27
|
0.73
|
1994-08-01
|
1994-03-25
|
0.73
|
1994-05-01
|
1994-01-03
|
0.73
|
1994-02-01
|
1993-09-27
|
0.72
|
1993-11-01
|
1993-06-28
|
0.72
|
1993-08-01
|
1993-03-29
|
0.72
|
1993-05-01
|
1993-01-04
|
0.72
|
1993-02-01
|
1992-09-28
|
0.69
|
1992-11-01
|
1992-06-26
|
0.69
|
1992-08-01
|
1992-03-30
|
0.69
|
1992-05-01
|
1991-12-27
|
0.69
|
1992-02-01
|
1991-09-30
|
0.60
|
1991-11-01
|
1991-06-28
|
0.60
|
1991-08-01
|
1991-04-01
|
0.60
|
1991-05-01
|
1990-12-28
|
0.60
|
1991-02-01
|
1990-10-01
|
0.53
|
1990-11-01
|
1990-06-29
|
0.53
|
1990-08-01
|
1990-04-02
|
0.53
|
1990-05-01
|
1989-12-29
|
0.53
|
1990-02-01
|
1989-09-19
|
0.50
|
1989-11-01
|
1989-06-30
|
0.50
|
1989-08-01
|
1989-04-03
|
0.50
|
1989-05-01
|
1988-12-30
|
0.50
|
1989-02-01
|
1988-10-03
|
0.42
|
1988-11-01
|
1988-06-27
|
0.42
|
1988-08-01
|
1988-03-25
|
0.42
|
1988-05-01
|
1988-01-04
|
0.42
|
1988-02-01
|
1987-09-28
|
0.35
|
1987-11-01
|
1987-06-26
|
0.35
|
1987-08-01
|
1987-03-30
|
0.70
|
1987-05-01
|
1986-12-26
|
0.70
|
1987-02-01
|
1986-09-29
|
0.55
|
1986-11-01
|
1986-06-27
|
0.55
|
1986-08-01
|
1986-03-31
|
0.55
|
1986-05-01
|
1985-12-07
|
0.47
|
1986-02-01
|
1985-09-30
|
0.47
|
1985-11-01
|
1985-06-08
|
0.47
|
1985-08-01
|
1985-03-09
|
0.47
|
1985-05-01
|
1984-12-08
|
0.40
|
1985-02-01
|
1984-10-01
|
0.40
|
1984-11-01
|
1984-06-29
|
0.40
|
1984-08-01
|
1984-04-02
|
0.40
|
1984-05-01
|
1983-12-30
|
0.30
|
1984-02-01
|
1983-10-03
|
0.30
|
1983-11-01
|
1983-07-01
|
0.30
|
1983-08-01
|
1983-01-03
|
0.52
|
1983-02-01
|
1982-10-04
|
0.52
|
1982-11-01
|
1982-07-02
|
0.52
|
1982-08-01
|
1982-04-04
|
0.60
|
1982-05-01
|
1982-04-02
|
0.52
|
1982-05-01
|
1982-01-04
|
0.46
|
1982-02-01
|
1981-10-05
|
0.46
|
1981-11-01
|
1981-07-06
|
0.46
|
1981-08-01
|
1981-04-06
|
0.46
|
1981-05-01
|
1981-01-05
|
0.40
|
1981-02-01
|
1980-10-06
|
0.40
|
1980-11-01
|
1980-06-30
|
0.40
|
1980-08-01
|
1980-03-27
|
0.40
|
1980-05-01
|
1979-12-27
|
0.36
|
1980-01-31
|
1979-10-04
|
0.36
|
1979-10-31
|
1979-06-28
|
0.36
|
1979-07-31
|
1979-04-01
|
0.36
|
1979-04-30
|
1978-12-28
|
0.31
|
1979-01-31
|
1978-10-01
|
0.31
|
1978-10-31
|
1978-06-29
|
0.31
|
1978-07-31
|
1978-03-30
|
0.31
|
1978-04-30
|
1977-12-29
|
0.28
|
1978-01-31
|
1977-10-02
|
0.28
|
1977-10-31
|
1977-06-26
|
0.28
|
1977-07-31
|
